biotech / news / / The Manila Times
Sanofi provides update on the regulatory submission for Sarclisa subcutaneous in the US.
The FDA has extended the Sarclisa subcutaneous target action date to July 23, 2026.
KEY POINTS
- If approved, Sarclisa would be the first anticancer treatment delivered via on-body injector.
- The European CHMP recommended Sarclisa subcutaneous for all indications of its IV formulation in March 2026.
- Sarclisa subcutaneous is being reviewed for use with all currently approved multiple myeloma regimens.
COMPANIES
Summarized by Newsio from The Manila Times. How we summarize →